Drug intelligence / Profile preview

ACM-005++

Development stage: Preclinical
Lead developer: ACM Biolabs
Modality: MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular

Overview

**ACM-005++** is an ACM Biolabs preclinical oncology immunotherapy program described in the company's pipeline as an oligonucleotide-based CpG adjuvant combination. It is intended to stimulate antitumor immunity through combined agonism of Toll-like receptor 9 and Toll-like receptors 7 and 8, thereby promoting innate immune activation in cancer. ([acmbiolabs.com](https://acmbiolabs.com/wp-content/uploads/ACM_Pipeline_Aug_2023_new.webp))

Targets

TLR9 (Toll-like receptor 9)

Beyond the preview

Go deeper on ACM-005++.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACM-005++.

Explore the full profile